Crystalys Therapeutics - Passionate. Dedicated. We improve lives.
Science & Engineering · Health Care
Funding and backers
Team
501-1000
employees, estimated range
Backers
4
Xontogeny, Lightstone Ventures
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Xontogeny 
Lightstone Ventures 
Pontifax 
SR One Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Changing the Trajectory of Parkinson's disease. JLABS San Diego San Diego, CA 92121USA.
LATEST NEWS. 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi Thane (W) 400 604, IndiaTel: +91-22-4170 3200Fax: +…
Fast Charge Engineering S.r.l. Battery systems for high power applications Latest News.
0 On-demand guidance from an attorney to get you home safe. Latest News and Updates What is TurnSignl?
Industry Trackers. Follow here for all the latest news about mergers, acquisitions and joint partnerships in the healthcare industry.
Business News: Get latest news on share market, personal finance news, economy news, stock market updates, company news, election results…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Show all 4 Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
His father suffered from gout in silence. Now a San Diego scientist is bringing the cure home
San Diego company is in the final phase of testing a drug to treat gout, a chronic condition.
Read more
Report
Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug
Crystalys's dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecule that Sobi added to its pipeline through a $950 million acquisition.
Read more
Report
Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout
Financing led by Frazier Life Sciences with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management,...
Read more
Report
Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout
/PRNewswire/ -- Crystalys Therapeutics Inc. (
Read more
Report
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites
/PRNewswire/ -- Crystalys Therapeutics, a clinical-stage biopharmaceutical company addressing the significant unmet medical needs of people living with gout,...
Read more
Report
Crystalys Therapeutics Expands Leadership Team with Appointment of Justin Thacker as Chief Financial Officer to Support Advancement of Phase 3 Trials of Dotinurad
/PRNewswire/ -- Crystalys Therapeutics, Inc. (
Read more
Report
Crystalys Therapeutics Launches with $205M Series A Financing to Transform the Treatment of Gout
Novo Holdings, SR One and Catalys Pacific co-led the financing Company emerges from stealth to advance lead asset, dotinurad, through global Phase 3 clinical...
Read more
Report